Product Launch Details

Zydus Lifesciences Limited launched REVAHALE™ (Revefenacin), India's first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).

Product Features and Differentiation

REVAHALETM is the first and only LAMA available in India that combines once-daily dosing with nebulized administration. The product offers:

  • Sustained 24-hour bronchodilation with a single daily dose
  • Compatibility with standard jet nebulisers
  • Reduced dependence on inhalation technique and inspiratory flow
  • Convenient nebulised delivery platform for patients and caregivers

Target Market and Medical Need

COPD remains a significant public health challenge in India and is a leading cause of morbidity and mortality. The product addresses unmet needs for patients who:

  • Experience difficulties using handheld inhalers
  • Have cognitive limitations
  • Suffer from severe breathlessness
  • Cannot generate sufficient inspiratory effort for effective drug delivery
  • Are elderly patients or those with severe respiratory impairment

Clinical Profile

Revefenacin is designed to deliver sustained bronchodilation over 24 hours through once-daily administration. Clinical studies have demonstrated:

  • Significant and sustained improvements in lung function
  • Efficacy in patients with moderate to very severe COPD
  • Favourable safety profile
  • Lung-selective design to maximise bronchodilatory effects while minimising systemic exposure

Strategic Significance

The launch represents an innovative, first-in-class product introduction in the Indian market, aligning with Zydus's mission to transform lives through pathbreaking discoveries and address unmet healthcare needs.

Company Background

Zydus Lifesciences Ltd. employs over 30,000 people worldwide, including 1,500 scientists engaged in R&D. The group has introduced several innovative, first-in-class products over the last decade for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities.